Natco to partner Lupin to market generic breast cancer drug

Hyderabad-based Natco Pharma has filed an abbreviated new drug application with US Food and Drugs Administration for a generic version of Lapatinib Ditosylate tablets of 250 mg strength, used for the treatment of breast cancer. Natco said it has partnered with Lupin to market the product.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Moneycontrol Bureau

Hyderabad-based Natco Pharma has filed an abbreviated new drug application with US Food and Drugs Administration for a generic version of Lapatinib Ditosylate tablets of 250 mg strength, used for the treatment of breast cancer. Natco said it has partnered with Lupin to market the product.

Natco

Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes